The pharmaceutical technology landscape: A new form of technology roadmapping

Technological Forecasting and Social Change

Volumn 80, Issue 2, 2013, Pages 194-211

  Tierney, Robert ^a   Hermina, Wahid ^b   Walsh, Steven ^c  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b SANDIA NATIONAL LABORATORIES   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Constrained innovations; Convergence; Creative enterprise; MEMS; Microtechnology; Nanotechnology; National laboratories; Technology entrepreneurship; Technology landscape; Technology roadmaps

Indexed keywords

CONVERGENCE; CREATIVE ENTERPRISE; MICROTECHNOLOGY; NATIONAL LABORATORY; TECHNOLOGY ENTREPRENEURSHIP; TECHNOLOGY LANDSCAPES; TECHNOLOGY ROADMAPS;

INDUSTRIAL MANAGEMENT; INDUSTRY; MEMS; NANOTECHNOLOGY; TECHNOLOGY;

INNOVATION;

BUSINESS DEVELOPMENT; CONVERGENCE; ENTREPRENEUR; INNOVATION; NANOTECHNOLOGY; PHARMACEUTICAL INDUSTRY; TECHNOLOGICAL DEVELOPMENT;

EID: 84871937176     PISSN: 00401625     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.techfore.2012.05.002     Document Type: Article

References (145)

1. Abbott 12/9/2010. http://www.abbott.com/global/url/content/en_US/10.20:20/general_content/General_Content_00007.htm.
2. Abernathy W.J., Utterback J.M. Patterns of industrial innovation. Technol. Rev. 1978, 50(7):40-47.
3. Adams C.P., Branter V.V. Estimating the cost of new drug development: is it really $802 million?. Health Aff. 2006, 25(2):420-428.
4. Albright R. How to use roadmapping for global platform products 12/8/2011. http://www.technologyforge.net/enma/6020/6020Lectures/TechnologyRoadmapping/ENMA291TRReferences/RoadmappingAlbright.pdf.
5. Alt R., Oestele H., Puschmann T., Barak V., Huber T. Customer relationship management architecture in the pharma industry. Int. J. Health Technol. Manage. 2003, 5(3):296-314.
6. Allarakhia M., Walsh S. Managing knowledge assets under conditions of radical change: the case of the pharmaceutical industry. Technovation 2011, 31(105):105-117.
7. Allarakhia M., Walsh S.T. Analyzing and organizing nanotechnology developments: Application of the institutional analysis development framework to nanotechnology consortia. Technovation 2012, 32(3-4):216-226.
8. Allarahia M., Wensley A. Systems biology: a disruptive biopharmaceutical research paradigm. Technol. Forecast. Soc. 2007, 74(9):1643-1660.
9. Allhoff F. The coming era of nanomedicine. Am. J. Bioeth. 2009, 9(10):3-11.
10. Amer M., Daim T.U. Application of energy roadmaps for renewable energy sector. Technol. Forecast. Soc. 2010, 77(8):1355-1370.
11. Arden W.M. The international technology roadmap for semiconductors-perspectives and challenges for the next 15 years. Curr. Opin. Solid State Mater. Sci. 2002, 6(5):371-377.
12. Ashford N.A. Incorporating science, technology, fairness, and accountability in environmental, health, and safety decisions. Hum. Ecol. Risk Assess. 2005, 11(1):85-96.
13. AsuteSolutions Solutions for the pharmaceutical industry 12/09/2011. http://www.astutesolutions.com/industries-pharmaceuticals.php.
14. Bainbridge W.S., Roco M. Managing Nano-Bio-Info-Cogno Innovations 2006, Springer, Netherlands. 1st ed.
15. Baker R., Smith D.J.H. Technology foresight using roadmaps. Long Range Plann. 1995, 28(2):21-28.
16. Beeuwkes Buntin M., Damberg C., Haviland A., Kapur K., Lurie N., McDevitt R., Marquis M.S. Consumer directed health care: early evidence about effects on cost and quality. Health Aff. 2006, 25(6):516-530.
17. Beugelsdijk T., Varma S., Walsh S. Ch. 4 BioMEMS, international roadmap on MEMS. Microsystems, Micromachining and Top Down Nanotechnology 2003, 109-157. MANCEF, Naples, Florida.
18. Bissell M., Sanfilippo F. Empowering patients with point-of-care testing. Trends Biotechnol. 2002, 20(6):269-270.
19. Boardman P. Beyond the stars: the impact of affiliation with university biotechnology centers on the industrial involvement of university scientists. Technovation 2008, 28:291-297.
20. Bonett B. Getting up close and personal with your genome. Cell 2008, 133(5):753-756.
21. Boohaker E.A., Ward R.E., Uman J.E., McCarthy B.D. Patient notification and follow-up of abnormal test results: a physician survey. Arch. Intern. Med. 1996, 156(3):327-331.
22. Borch K. Refining the debate on GM crops using technological foresight - the Danish experience. Technol. Forecast. Soc. 2005, 72(5):549-566.
23. Chaisson R.E., Keruly J.C., McAvinue S., Gallant J.E., Moore R.D. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 1996, 15 11(5):455-459.
24. Chan M. Global health diplomacy: negotiating health in the 21st century Director-General of the World Health Organization. Address at the Second High-level Symposium on Global Health Diplomacy 12/6/2011, http://www.who.int/dg/speeches/2008/20081021/en/index.html.
25. Chesbough H., Kardo A. Beyond high tech: early adopter of open innovation in other industries. R&D Manage. 2006, 36(3):229-236.
26. Christensen C., Burgelman R.A., Wheelwright S.C. Strategic Management of Technology and Innovation 2008, McGraw-Hill/Irwin, Columbus, OH. 5th ed.
27. Christensen C.M. The Innovators Dilemma: The Revolutionary Book that Will Change the Way You Do Business 2003, Harper Collins Publications, New York, New York.
28. Christopher P., Adams V.V., Dickson M., Gagnon P. Key factors in the rising cost of new drug discovery and development. Nat. Rev. Drug Discov. 2004, 3:417-429.
29. Coates J.F. Technological change and future growth: issues and opportunities. Technol. Forecast. Soc. 1977, 11(1):49-74.
30. Cooper R. Perspective third-generation new product processes. J. Prod. Innov. Manage. 1994, 11(1):3-14.
31. Daim T.U., Oliver T. Implementing technology roadmap process in the energy services sector: a case study of a government agency. Technol. Forecast. Soc. 2008, 75(5):678-720.
32. Dickson M., Gagnon P. Key factors in the rising cost of new drug discovery and development. Nat. Rev. Drug Discovery 2004, 3:417-429.
33. Dutifield G. Intellectual Property Rights and the Life Sciences Industries: A Twentieth Century History 2003, Ashgate Publishing Limited, Burlington VT.
34. Eijkel K., Knol E., Walsh S. Converging technologies 12/05/2010. http://www.itrs.net.
35. Eisenhardt K.M. Building theories from case study research ACD. Manage Rev. 1989, 14(4):532-550.
36. Eisenhardt K.M., Graebner M.E. Theory building form cases: opportunities and challenges. Acad. Manage. J. 2007, 50(1):25-32.
37. Fink M., Lang R., Harms R. Local responses to global technological change - contrasting restructuring practices in two rural communities in Austria. Technol. Forecast. Soc. 2013, 80(2):243-252. (this issue).
38. Fisher J.C., Pry R.H. Simple substitution model of technological change. Technol. Forecast. Soc. 1971-1972, (3):75-88.
39. Foster R.N. Innovation: The Attracter's Advantage 1985, Summit Books, Manila Philippines. 1st ed.
40. Fowler F.J. Survey Research Methods (Applied Social Research Methods) 2008, Sage, Thousand Oaks, CA. 4th ed.
41. Franses P.H. A method to select between Gompertz and logistic trend curves. Technol. Forecast. Soc. 1994, 46(1):45-49.
42. Garcia M.L., Bray O.H. Fundamentals of technology roadmapping, Sandia National Labs press release SAND97-0665 http://www.sandia.gov/PHMCOE/pdf/Sandia'sFundamentalsofTech.pdf.
43. Genentech 12/07/2011. http://www.gene.com/gene/research/focusareas/.
44. de Graaf H.J., Noordervliet M.A.W., Musters C.J.M., de Snoo C.J.M.G.R. Roadmap for interactive exploration of sustainable development opportunities: the use of simple instruments in the complex setting of bottom-up processes in rural areas. Land Use Policy 2009, 26(2):295-307.
45. Groenveld P. Roadmapping integrates business and technology. Res. Technol. Manage. 1997, 40(5):48-55.
46. Gross C., Allen J. Technology Transfer for Entrepreneurs: A Guide to Commercializing Federal Laboratory Innovations 2003, Praeger Publishing, Westport CT.
47. Haines K.R., Smith D., Anderson P.R., Epstein A.J., McMichael I., Roberts P., Wilkinson J., Woodcock J., Woods J. Polices for accelerating access to clean energy, improving health, advancing development and mitigating climate change. Lancet 2007, 370(9594):6-12. (1264 128).
48. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
49. Dolomite MicroFluidic Products 12/09/2010. http://www.dolomite-microfluidics.com/en/products.
50. Harmon A. Gene map becomes a luxury item new times http://www.nytimes.com/2008/03/04/health/research/04geno.html.
51. Hernandez-Ortega B. The role of post-use trust in the acceptance of a technology: drivers and consequences. Technovation 2011, 31(10-11):523-538.
52. Hilgartner S. Access to Data and Intellectual Property: Scientific Exchange in Genome Research. Intellectual Property Rights and Research Tools in Molecular Biology 1996, 28-33. National Academy Press, Washington DC.
53. Hinkebein T., Price M.K. Progress with the desalination and water purification technologies U.S. Desalination 2005, 182(1-3):19-28.
54. Huang Q., Yu H., Ru Q. Bioavailability and delivery of nutraceuticals using nanotechnology. J. Food Sci. 2010, 75(1):50-57.
55. Human Genome Project information on the Human Genome Project 12/09/2011. http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml.
56. International technology roadmap for semiconductors 2008 update 79. http://www.itrs.net/links/2008ITRS/Update/2008_Update.pdf.
57. Jones A.J.S., Cleland J.L. Technical and regulatory hurdles in delivery aspects of macromolecular drugs. J. Control Release 1996, 41(1-2):147-155.
58. Kilby J. Turning potential into realities: the invention of the integrated circuit. Chemphyschem 2000, 2(8/9):482-489.
59. Lee S., Park Y. Customization of technology roadmaps according to roadmapping purposes: overall process and detailed modules. Technol. Forecast. Soc. 2005, 72(5):567-583.
60. Linton J.D., Walsh S. Acceleration and extension of opportunity recognition for nanotechnologies and other emerging technologies. Int. Small. Bus. J. 2006, 26:83-99.
61. Linton J.D., Walsh S. Integrating innovation and learning curve theory: an enabler for moving nanotechnologies and other emerging process technologies into production. R&D Manage. 2004, 34(5):513-522.
62. Lubitz J., Beebe J., Baker C. Longevity and medicare expenditures. N. Engl. J. Med. 1995, 332:999-1003.
63. Lum P.Y., Armour C.D., Stepaniant S.B., Cavet G., Wolf M.K., Scott Butler J., Hinshaw J.C., Garnier Philippe, Prestwich G.D., Leonardson Amy, Garrett-Engele Philip, Rush C.M., Bard M., Schimmack G., Phillips J.W., Roberts C.J., Shoemaker D.D. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 2004, 116(1):121-137.
64. Kirchhoff B.A. Entrepreneurship and Dynamic Capitalism: the Economics of Business Firm Formation and Growth 1994, Praeger, Westport, Conn.
65. Kirchhoff B., Walsh S. Entrepreneurs' opportunities in technology-based markets. Research in Entrepreneurship and Management 2002, 17-30.
66. Kirchhoff B., Walsh S. Entrepreneurship's role in commercialization of disruptive technologies band 13. Unternehmer und Unternehmensperspektive fur Klien-und Mittelunternehmen 2000, 323-332. Dunker & Humbolt, Berlin/St. Gallen.
67. Kirzner I.M. How markets work: disequilibrium, entrepreneurship and discovery. IEA Hobart Paper No. 133 1997, London Institute for Economic Affairs.
68. Kirzner I.M. Competition and Entrepreneurship 1973, University of Chicago Press, Chicago, Ill.
69. Korotayev J., Zinkina J., Bogevolnov J. Kondratieff waves in global invention activity. Technol. Forecast. Soc. 2011, 78(7):1280-1284.
70. Kostoff R.N., Schaller R.R. Science and technology roadmaps. IEEE Trans. Eng. Manage. 2001, 48(2):132-143.
71. Kroc S., Delic V. Personal wireless sensor network for mobile health care monitoring. Telecommunications in Modern Satellite. Cable and Broadcasting Service TELSIKS 6th International Conference 2004, 2(1-3):471-474.
72. Lyles A. Direct marketing of pharmaceuticals to consumers. Rev. Public Health 2002, 23:73-91.
73. MacDailyNews Obama signs first-to-file U.S. patent reform bill into law 2011 9/16/2011. http://macdailynews.com/2011/09/16/obama-signs-first-to-file-u-s-patent-reform-bill-into-law/.
74. Mangematin V., Amir-Aslani A. The future of drug discovery and development: shifting emphasis towards personalized medicine. Technol. Forecast. Soc. 2010, 77(2):203-217.
75. Mankins J.C. Technology readiness levels white paper office of space access and technology NASA April 6, 1995 http://ehbs.org/trl/Mankins1995.pdf.
76. G. Marinkas, R. Tierney and D. Walsh, Are nanotechnology researchers, developers and their managers addressing health and safety concerns through publications and or patent applications, J. Bus. Ethics. in press.
77. Markus A. Tiny magnets could clear diseases from the blood technology review 12/07/2011. http://www.technologyreview.com/biomedicine/39181/?mod=chfe.
78. McDowall W. Technology roadmaps for transition management: The case of hydrogen energy. Technol. Forecast. Soc. 2012, 79(3):530-542.
79. McGrath S.P., Grigg E., Wendelken S., Blike G., De Rosa M., Fiske A., Gray R., Artemis R. A vision for remote triage and emergency management information integration 2011. http://www.ists.dartmouth.edu/library/15.pdf.
80. Micro and Nanotechnology Commercialization Education Foundation (MANCEF) Commercialization of Micro Nano Systems Conference 2011.
81. Micro, Nanotechnology Commercialization Education Foundation (MANCEF) Roundtable discussion by life science investors. Albuquerque, New Mexico 2010.
82. Micro, Nanotechnology Commercialization Education Foundation (MANCEF) International Micro/Nano Roadmap 2011, 3rd ed.
83. Moore G. Lithography and the future of Moore's law. Solid State Circuits Newsl. 2006, 20(3):37-42.
84. Morgan S., Hurley J. Influences on the health care technology cost-driver commission on the future of health care in Canada. Discussion Paper 14 2002, 22.
85. Nike Fuel Band http://store.nike.com/us/en_us/?l=shop,pwp,c-1+100701/hf-4294899078+12003+50142&cp=USNS_KW_0611081618.
86. Ness J., Cirilla D.J., Weir D.R., Nisley N.L., Wallace R.B. Use of complementary medicine in older Americans: results from the health and retirement study. Gerontologist 2004, 45(4):516-524.
87. NERAC New perspectives on the future of drug discovery 12/09/2011. http://www.nerac.com/nerac_insights.php?category=reports&id=7.
88. New York Times, First to File Bill, December 10, 2011, , New York 2011.http://topics.nytimes.com/top/news/science/topics/inventions_and_patents/index.html.
89. Noyce R.N. Carrier generation and recombination in P-N junctions and N-P junctions characteristics. Proc. IRE 1957, 45(9):1228-1243.
90. Phaal R., O'Sullivan E., Routley S., Probert D. A framework for mapping industrial emergence. Technol. Forecast. Soc. 2011, 72(2):217-230.
91. Phaal R., Clare J.P.F., Probert D. Technology roadmapping - a planning framework for evolution and revolution. Technol. Forecast. Soc. 2004, 71(1-2):5-26.
92. Population Profile of the United States 12/8/2011. http://www.census.gov/population/www/pop-profile/natproj.html.
93. Porter A. Forecasting and Management of Technology 2011, Wiley, Somerset, NJ. 2nd ed.
94. Poupard J.A., Miller L.A. Biological Warfare Encyclopedia of Microbiology 2009, Philadelphia PA. 3rd ed.
95. Pradhan M., Sahn D.E., Younger S. Decomposing world health inequalities. J. Health Econ. 2003, 22(2):27.
96. Prina L.D., White R.D., Atkinson E.J. Automated external defibrillators and first responders: a satisfaction survey. Resuscitation 2002, 53(2):171-177.
97. Rathore S.A. Roadmap for implementation of Quality by Design (QbD) for biotechnology products. Trends Biotechnol. 2009, 27(9):546-553.
98. Rinne M. Technology roadmaps: infrastructure for innovation. Technol. Forecast Soc. 2004, 71(1-2):67-80.
99. Roco M.C. Broader societal issues of nanotechnology. J. Nanopart. Res. 2003, 5:181-189.
100. Romig A.D., Baker A.B., Johannes J., Zipperian T., Eijkel K., Kirchhoff B., Mani H.S., Rao C.N.R., Walsh S. An introduction to nanotechnology policy: opportunities and constraints for emerging and established economies. Technol. Forecast Soc. 2007, 74(9):1634-1642.
101. Kostoff R.N., Boylan R., Simons G. Disruptive technology roadmaps. Technol. Forecast Soc. 2004, 71(1-2):141-159.
102. Satava R.M. Virtual reality and teleprescence for military medicine. Comput. Biol. Med. 1995, 25(2):229-236.
103. Shin D.H. Potential user factors driving adoption of IPTV. What are customers expecting from IPTV?. Technol. Forecast Soc. 2007, 74(8):1446-1464.
104. Wanzer S.H., Adelstein S.J., Cranford R.E., Federman D.D., Hook E.D., Moertel C.G., Safar P., Stone A., Taussig H.B., van Eys J. The Physician's Responsibility toward Hopelessly Ill Patients. N. Engl. J. Med. 1984, 310:955-959.
105. Som C., Hilty L.M., Köhler A.R. The precautionary principle as a framework for a sustainable information society. J. Bus. Ethics 2009, 85:493-505.
106. Styhre A. Institutionalizing technoscience: post-genomic technologies and the case of systems biology. Scand. J. Manag. December 2011, 27(4):375-388.
107. Tudos A.J., Besselink G.A.J., Schasfoort R.B.M. Trends in miniaturized total analysis systems for point of care in clinical chemistry. Lab. Chip. 2001, 1:83-95.
108. Tura A., Maran A., Pacini G. Non-invasive glucose monitoring: assessment of technologies and devices to quantitative criteria. Diabetes Res. Clin. Pract. 2007, 77(1):16-40.
109. Eijkel K., Hruby J., Kubiak G., Scott M., Brokaw J., Saile V. Steven Walsh, Craig White and Daniel Walsh, Commercial importance of a unit cell: nanolithographic patenting trends for microsystems, microfabrication, and nanotechnology. J. Microlith. Microfab. Microsyst. 2006, 5:11-14.
110. Shockley W. The path to the conception of the junction transistor. IEEE Electron Device Lett. 1976, 23(7):597-620.
111. Srinivas P.R., Baker P., Srivastava S. Nanotechnology in early detection of cancer. Lab. Invest. 2002, 82:657-662.
112. Stebbing M. Avoiding the trust deficit: public engagement, values, the precautionary principle and the future of nanotechnology. J. Bioethical. Inq. 2009, 6:37-48.
113. Steward M., Brown J.B., Donna A., McWhinney I., Oates J., Weston W.W., Jordan J. The impact of patient centered care on outcomes. Fam. Pract. 2000, 49(9). (http://www.ucdmc.ucdavis.edu/ome/mcrtp/docs/Kravitz%20The%20impact%20of%20patient-centered%20care%20on%20outcomes.pdf2011).
114. Technology readiness levels handbook for space operations Issue 1, Revision 6 September 2008, J 1/1/2012. https://telecom.esa.int/telecom/media/document/TRL_Handbook.pdf.
115. R. Tierney, R. Harms, A. Groen, H. Stewart, D. Hetherington, M. Luzink, J. Linton, and S. Walsh, Managing highly flexible facilities - an essential complementary asset at risk, Int. J. Entrepreneurial Behav. Res. (in press).
116. U.S.Clean Air Act 1/13/2012. http://www.epa.gov/lawsregs/laws/caa.html.
117. U.S.Department of Health Personalized Health Care 12/09/2011. http://www.hhs.gov/myhealthcare.
118. Uwe R.E. Does the aging of the population really drive the demand for health care does the aging of the population really drive the demand for health care. Health Aff. 2003, 22(6):27-39.
119. Vallance P., Levick M. Drug discovery and development in the age of molecular medicine perspectives. Clin. Pharmacol. Ther. 2007, 82(4):363-366.
120. Walsh S. Roadmapping a disruptive technology: a case study: the emerging microsystems and top down nanosystems industry. Technol. Forecast. Soc. 2004, 71(1-2):161-185.
121. Walsh S., Boylan R., McDermott C., Paulson A. The semiconductor silicon industry roadmap: epochs driven by the dynamics between disruptive technologies and core competencies. Technol. Forecast. Soc. 2005, 72(2):213-236.
122. Wylde J., Walsh S., et al. The International RF MEMS Road map 2005, 122. MANCEF, Naples, Florida.
123. The Second Edition of the International Micro-Nano Roadmap 2004, 674. MANCEF, Naples, Florida. S. Walsh, R. Giasolli, J. Elders (Eds.).
124. Walsh S., Kirchhoff B., Newbert S. Differentiating market strategies for disruptive technologies. IEEE Trans. Eng. Manage. 2002, 49(4):341-351.
125. International Roadmap on MEMS, Microsystems. Micromachining and Top Down Nanotechnology 2003, 614. MANCEF, Naples, Florida. S. Walsh, J. Elders (Eds.).
126. Walsh S., Linton J., Grace R., Marshall S., Knutti J. MEMS, Microsystems, Micro machines: Commercializing An Emergent Disruptive Technology, in MEMS and MOEMS Technology and Applications 2000, 479-514. SPIE - The International Society for Optical Engineering Development, Billingham, Washington. P. Rai-Choudry (Ed.).
127. Walsh S., Wylde J. Ch. 2 RF MEMS. International Micro-Nano Roadmap 2004, 40-152. MANCEF, Naples, Florida. 2nd ed.
128. Walsh S., Wylde J. The international RF MEMS road map 2005, 122. MANCEF, Naples, Florida.
129. Weiss J., Takhistov P., McClemments D. Functional materials in food nanotechnology. J. Food Sci. 2006, 71(9):107-116.
130. Willyard C.H., McClees C.W. Motorola's technology roadmap process. Res. Manage. 1987, 30(5):13-19.
131. Williamson O.E. The Economic Institutions of Capitalism 1985, Free Press, New York N.Y.
132. Wonglimpiyara J. The nano-revolution of Schumpeter's Kondratieff cycle. Technovation 2005, 25:1349-1354.
133. World population ageing: 1950-2050 united nations 12/7/2011. http://www.un.org/esa/population/publications/WPA2007/WORLD%20POPULATION%20AGEING%202007.pdf.
134. World population to reach 10 billion by 2100 if fertility in all countries converges to replacement level http://esa.un.org/wpp/Other-Information/Press_Release_WPP2010.pdf.
135. Yasunaga Y., Watanabe M., Korenaga M. Application of technology roadmaps to governmental innovation policy for promoting technology convergence. Technol. Forecast. Soc. 2009, 76(1):61-79.
136. Yin R.K. Case Study Research: Design and Methods 2003, Sage Publishers. 3rd ed.
137. Zaffaroni A. ALZA: an enterprise in biomedical innovation. Technovation 1981, 1(2):135-146.
138. Zevalin Information on Zevalin pharmacology 12/09/201. http://zevalin.com/v3/zevalin-rit/index.htm.
139. Zoorob R., Morelli V. Disease prevention and wellness in the twenty-first century. Prim. Care 2008, 35(4):663-667.
140. Roco M.C. Progress in Governance of Converging Technologies Integrated from the Nanoscale. ANN NY Acad. Sci. 2006, 1093:1-23.
141. Foster R.N. Innovation: The Attackers Advantage 1986, Summit Books, New York, New York.
142. Fowler F.J. Survey Research Methods 4ed 2008, Sage Publications, Thousands Oaks, Ca.
143. Roco M., Mirkin C.A., Hersam M.C. Nanotechnology research directions for societal needs in 2020: Retrospective and Outlook 2011, Springer, New York, New York.
144. Anderson G.F., Reinhardt U.E., Hussey P.S., Petrosyan V. It's the Prices Stupid: Why the United States is so different from other countries. Health Affairs 2003, 22(3):89-105.
145. Linton J.D., Walsh S.T. Acceleration and Extension of Opportunity Recognition for Nanotechnologies and Other Emerging Technologies. Int. Small Bus. J. 2008, 26(1):83-99.